Unknown

Dataset Information

0

Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison.


ABSTRACT: BACKGROUND:Opioid use disorder is common in prison populations, and prison release is a high-risk time for relapse and overdose. Initiation of extended release injectable naltrexone (XR-NTX)) prior to prison release might decrease relapse among opioid-dependent persons. OBJECTIVE:This pilot study examined the feasibility and acceptability of XR-NTX injection prior to prison release among adult inmates with opioid use disorder, followed by six months of community XR-NTX treatment. It sought to determine effects on treatment retention and abstinence compared to post-release XR-NTX initiation. METHODS:Recruitment for the study took place at the RIDOC's Adult Correctional Institute (ACI). Volunteers with a history of opioid dependence and a release date scheduled within 1-2months were self-referred in response to recruitment fliers. Consented volunteers were randomized to XR-NTX treatment prior to release followed by 5 monthly treatments in the community (pre-release) or six XR-NTX treatments in the community (post-release). RESULTS:Of 26 volunteers consented, 15 were randomized (9 pre-release, 6 post-release). The pre-release group generally had better treatment retention: 100% received the first NTX injection (vs. 67% post-release), 78% received more than one injection (vs. 17%) and 22% received all 6 injections (vs. 0%). The pre-release group also had greater abstinence, with a higher proportion of self-reported opioid free days in the first month after release (83% vs. 46%, fewer positive urine drug tests in the 6months after release (22% vs. 33%), and more days of opioid receptor blockade during the first two weeks after release, a high risk time for overdose death. CONCLUSIONS:Initiation of XR-NTX injection prior to release from prison might be an effective approach to reduce relapse to opioids, but these findings require confirmation in a larger trial.

SUBMITTER: Friedmann PD 

PROVIDER: S-EPMC5648627 | biostudies-literature | 2018 Feb

REPOSITORIES: biostudies-literature

altmetric image

Publications

Initiation of extended release naltrexone (XR-NTX) for opioid use disorder prior to release from prison.

Friedmann Peter D PD   Wilson Donna D   Hoskinson Randall R   Poshkus Michael M   Clarke Jennifer G JG  

Journal of substance abuse treatment 20170419


<h4>Background</h4>Opioid use disorder is common in prison populations, and prison release is a high-risk time for relapse and overdose. Initiation of extended release injectable naltrexone (XR-NTX)) prior to prison release might decrease relapse among opioid-dependent persons.<h4>Objective</h4>This pilot study examined the feasibility and acceptability of XR-NTX injection prior to prison release among adult inmates with opioid use disorder, followed by six months of community XR-NTX treatment.  ...[more]

Similar Datasets

| S-EPMC5993595 | biostudies-literature
| S-EPMC7433932 | biostudies-literature
| S-EPMC5455014 | biostudies-literature
| S-EPMC7260104 | biostudies-literature
| S-EPMC5454800 | biostudies-literature